Shares of Johnson & Johnson JNJ, -0.73% were up 0.1% in premarket trading on Tuesday after the company said it brought in $502 million in worldwide sales of its COVID-19 vaccine in the third quarter of 2021 as part of its earnings report. That adds up to a total of $766 million in sales of its COVID-19 shot so far this year. J&J’s stock is up 1.7% for the year, while the broader S&P 500 SPX, +0.34% has gained 19.4%.
View Article Origin Here
